Novel Treatments for Varicose Veins

Further innovations

Many recent innovations are currently under evaluation as potential new methods to treat varicose veins in a painless way. Currently avaiable treatments have some limitations which can be overcome but it is possible that newer methods may lead to less complexity in the management of varicose veins.

Clarivein

ClariVein® is the new Endovascular technique for the treatment of venous reflux disease; the procedure was pioneered in the USA along with internationally recognised surgeons from different countries.

This revolutionary device has significant benefits for Clinicians, Patients, and Health Care Providers:

Safe and effective technique with no need for tumescent anesthesia.

Eliminates the risk of nerve or skin damage or parathesia from thermal energy.

Mechanical agitation of the vessel endothelia by the rotating catheter tip.

A sclerosant drug sprayed from the tip of the catheter as it is pulled back to ensure maximum effect.

ClariVein venous ablation

In this treatment, a rotating catheter is passed along the saphenous vein. As it is withdrawn, a sclerosing injection is introduced into the saphenous vein.ClariVein achieves occlusion of 90% of saphenous veins at 1 year according to published studies. This is very simlar to other minimally invasive methods. The conclusions reached so far are based on a limited number of clinical series followed up for 1 – 2 years. Long term efficacy is yet to be established. This is a promising technique but it is not yet clear whether it has advantages over foam sclerotherapy which is technically less complex.

Saphenon VenaSeal

Sapheon VenaSeal – glue obliteration of varicose veins.

In this treatment a catheter is passed along the spahenous vein and then withdrawn as drops of cyanoacrylate glue are deposited in the vein. The vein is compressed for a few seconds afterwards. This treatment results in immediate obliteration of the saphenous vein. Some cases of phlebitis have been reported afterwards. Very limited clinical information has been reported following this treatment although a European clinical trial is current in progress.